Immunogenicity of panitumumab in combination chemotherapy clinical trials

Table 3 Distribution of the observed concentrations of panitumumab relative to the 90% predictive interval

Distribution in Relation to 90% Prediction Interval	Antibody-Positive Patients				Antibody-Negative Patients				P-value^†
	N	%	95% CI	P-value*	N	%	95% CI	P-value*
Below	2	5.3	0.6 -17.8	0.07	3	4.4	0.9 - 12.4	0.13	0.88
Above	5	13.2	4.4 - 28.1		7	10.3	4.2 - 20.1
Within	31	81.6	65.7 - 92.3		58	85.3	74.6 - 92.7

*Chi-square test with hypothesized proportions (5% below, 5% above, 90% within).
^†Chi-square test of antibody-positive proportion vs antibody-negative proportion.